Document resource
Background and Importance Pharmacotherapy is an integral part of healthcare delivery; however, its inappropriate use can lead to drug-related problems (DRPs), which negatively impact the desired clinical outcomes of pharmacotherapy and the patient’s health status. The consulting activities of a pharmacist in a hospital pharmacy play a crucial role in identifying and resolving DRPs, thereby contributing to safer and more effective pharmacotherapy.Aim and Objectives The aim of this study was to analyse the occurrence of DRPs in hospitalised patients and to evaluate the effectiveness of pharmaceutical interventions within consulting activities.Materials and Methods The research was conducted at the Central Slovak Institute of Cardiovascular Diseases in Banská Bystrica between October 2024 and February 2025. Data were obtained through the PROMIS medical information system, with patients selected based on excessive polypharmacy (≥10 medications) and the presence of at least one severe drug interaction. DRPs were classified according to the PCNE (Pharmaceutical Care Network Europe) classification system (version 9.1), and pharmaceutical interventions were assessed based on their acceptance and implementation into pharmacotherapy.Results In total, 60 patients were analysed, with 209 DRPs identified. The most common problems included inappropriate drug combinations (n=119), inappropriate treatment in elderly patients (n=38), inappropriate drug dosing (n=15), and unclear drug indications (n=14). Pharmacist interventions were fully accepted and implemented in 57% of cases, accepted but not implemented in 31%, partially implemented in 6%, and implementation status was unknown in the remaining 6%. Statistical analysis demonstrated a highly significant correlation between the number of medications taken and the occurrence of severe drug interactions (p=0.0001).Conclusion and Relevance The results confirm that the consulting activities of a pharmacist in a hospital pharmacy contribute to optimising pharmacotherapy, reducing the risk of DRPs, and increasing the safety of treatment for hospitalised patients.